A 48-year-old woman from Uttar Pradesh, known case of cervical cancer (stage IB2), has completed concurrent chemoradiotherapy (CCRT) with cisplatin. At 3 months post-treatment, imaging shows no residual disease. She now presents with severe vaginal stenosis and recurrent urinary tract infections. Which of the following is the MOST appropriate next step in her management?

Explanation

## Management of Post-CCRT Morbidity in Cervical Cancer **Clinical Context:** This patient has completed definitive CCRT for stage IB2 cervical cancer with complete response. The presenting symptoms—vaginal stenosis and recurrent UTIs—are **late iatrogenic toxicities** of radiotherapy, not indicators of residual/recurrent disease (imaging is clear). **Correct Answer: Serial Vaginal Dilations + Topical Estrogen** **Key Point:** Vaginal stenosis is a common late effect of pelvic radiotherapy (incidence 5–25% in cervical cancer survivors). Management is **conservative and preventive**: - **Serial vaginal dilations** (3–4 times weekly) prevent adhesion formation and maintain vaginal patency - **Topical estrogen** (cream or tablets) restores mucosal health, improves lubrication, and reduces stenosis progression - **Routine surveillance imaging** (6–12 monthly) detects recurrence early - This approach preserves quality of life and sexual function without additional toxicity **High-Yield:** Vaginal stenosis management is **non-surgical** unless severe stricture or complete obliteration occurs. Early intervention prevents need for surgical reconstruction. **Clinical Pearl:** The combination of vaginal stenosis + recurrent UTIs suggests **radiation-induced changes** (fibrosis, reduced vascularity) rather than active disease. Estrogen deficiency (from ovarian damage) worsens mucosal atrophy. ## Why Each Distractor Is Wrong **Option 1 (Adjuvant Brachytherapy):** - Brachytherapy is part of **primary treatment** for cervical cancer, not an adjuvant modality after CCRT - Patient has already received full-dose external beam RT + brachytherapy is typically integrated into CCRT protocol - Adding brachytherapy post-CCRT would cause **severe cumulative toxicity** (bowel perforation, fistula, hemorrhage) without survival benefit when disease is in complete remission - **Contraindicated** in this clinical scenario **Option 2 (Systemic Chemotherapy with Bevacizumab):** - Bevacizumab is indicated for **recurrent or metastatic cervical cancer**, not for adjuvant therapy in stage IB2 with complete response - No survival benefit for adjuvant bevacizumab in early-stage disease post-CCRT - Unnecessary toxicity (hypertension, proteinuria, GI perforation risk) in a patient with no evidence of disease - NCCN/FIGO guidelines do not recommend adjuvant systemic therapy for stage IB2 with complete CCRT response **Option 3 (Total Abdominal Hysterectomy + BSO):** - Hysterectomy is **not indicated** after successful CCRT for cervical cancer - Increases morbidity (bowel adhesions, fistula risk) in a previously irradiated pelvis without improving survival - Ovarian preservation (in premenopausal women) is preferred to avoid surgical menopause and long-term HRT risks - Surgery is reserved for **persistent/recurrent disease** (exenteration) or as primary treatment in select early-stage cases (not post-CCRT) --- **Summary Table:** | Intervention | Indication | Status in This Case | |---|---|---| | Serial dilations + topical estrogen | Late radiation toxicity (stenosis) | ✓ **Appropriate** | | Adjuvant brachytherapy | Primary treatment integration | ✗ Already given; cumulative toxicity | | Bevacizumab | Recurrent/metastatic disease | ✗ No disease; no survival benefit | | Hysterectomy | Persistent/recurrent disease | ✗ Complete response; increases morbidity |